BioValve Technologies, Inc.

BioValve Technologies, Inc. is a specialty pharmaceutical company founded in 1998 focusing on the development of new chemical entities that support the treatment of conditions of the central nervous system. The lead agents in BioValve’s portfolio are D1 and D2 selective dopamine agonists for treatment of Parkinson’s disease and schizophrenia.

For additional information on BioValve, Inc. please contact:

Corporate Headquarters
Biovalve Technologies, Inc.
9 Campus Drive, 2nd Floor East
Parsippany, NJ 07054

General Information Telephone: (508) 845-1177
General Facsimile: (508) 842-8928

Bob Gonnelli
President and Chief Executive Officer
Telephone: 973-993-1400 ext. 120
E-mail: bgonnelli@biovalve.net